Plain-English translation of NCT07206524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a research study for people already participating in the OMAGOD trial who receive hemodialysis three times a week. Researchers want to understand whether the chemical composition of dialysis fluid — specifically the amounts of magnesium and the type of acid used — affects how your immune cells and blood cells respond during treatment. The study will test three different dialysis fluid formulas over six weeks to see which composition causes the least inflammation and blood clotting problems.
People on long-term dialysis often experience unwanted blood clotting and inflammation, which can damage blood vessels and affect overall health. This study aims to find out if adjusting the dialysis fluid's mineral content could reduce these harmful effects and improve safety during treatment.
You likely qualify if…
You likely don't qualify if…
If you join, you will continue your regular dialysis schedule of three sessions per week for four hours each. During three specific dialysis sessions, researchers will collect small blood samples at the beginning, hourly during treatment, and at the end. They will also collect cells from the dialysis tubing after your session ends. This extra monitoring happens during selected weeks when you're using different dialysis fluid formulas — no additional visits beyond your normal dialysis appointments are needed.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Belgium
Sponsor
Universitair Ziekenhuis Brussel
Collaborators
University of Rochester, Vrije Universiteit Brussel
Enrollment target
~15 participants
Started
June 2025
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Florine Janssens, Medical doctor
(1)Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. (2) Kidney diseases, dialysis & transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.